Jump to    Selected Key Publications     Research Interests     Projects   

Clinical Trial Coordinator/ Paediatrician

Dr Olubukola T. Idoko is paediatrician who works as a clinical scientist at the Medical Research Council Unit in The Gambia. She has over 15 years of experience in clinical paediatrics with a focus on infectious diseases and new born care. She trained in Medicine at the University of Jos and subsequently paediatrics at the Jos University Teaching Hospital in Nigeria obtaining the fellowship of the West African College of Physicians in paediatrics. She also has training in in Public Health form the London School of Hygiene and Tropical Medicine and in Vaccinology. In addition to her role at the MRCG she provides support for medical student training as a lecturer at the University of The Gambia and does volunteer work. Driven by the stark health inequities in her early days of practise and overwhelming disease burden particularly in young infants, her current research interests centre on vaccines for paediatric infectious disease and  infectious disease epidemiology. She has been involved in and led the conduct of several clinical trials including driving the setup of clinical trial sites and is author of several articles and book chapters. Her passion is to optimize use of existing disease prevention interventions using approaches relevant to the setting and train qualitative health care professionals for the sub-Saharan region.


       Selected Key Publications

  1.  Idoko OT, Mboizi RB, Okoye M, Laudat F, Ceesay B, Liang JZ, Dren-Narayanin NL, Jansen KU, Gurtman A, Center KJ, Scott DA, Kampmann B, Roca A, Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine (PCV13) formulated with 2-phenoxyethanol in multidose vials given with routine vaccination in healthy infants: An open-label randomized controlled trial. Vaccine 2017; 35: 3256 - 63.
  2. Idoko OT, Hampton L, Mboizi RB, Agbla SC, Wallace AS, Harris JB, Sowe D, Ehlman DC, Kampmann B, Ota MO, Hyde TB. Acceptance of the Administration of Multiple Injectable Vaccines in a Single Immunization Visit in The Gambia Before and After Introduction of Inactivated Polio Vaccine (IPV). Vaccine 2016; 34: 5034 - 39.
  3. Idoko OT, Diallo A, Sow SS, Hodgson A, Akinsola A, Diarra B, Haidara FC, Ansah PO, Kampmann B, Bouma E, Preziosi MP, Enwere G, Community perspectives associated with the African PsA-TT  (MenAfriVac®) vaccine trials. CID 2015; S1 (S5): S416-21.
  4. Tapia M, Findlow H, Idoko OT, Preziosi MP, Kulkarni PS, Enwere GC, Elie C, Parulekar V, Sow SO, Haidara FC, Dia F, Doumbia M, Akinsola AK, Adegbola RA, Kampmann B, Chaumont J, Marchetti, Viviani S, Tang Y, Plikaytis BD, LaForce FM, Carlone G, Borrow R, Antibody Persistence 1 to 5 Years Following Vaccination with MenAfriVac in African Children Vaccinated at 12 to 23 Months of Age. CID 2015; S1 (S1): S514-20.
  5. Mackenzie GA,  Ikumapayi UNA,  Scott S, Idoko O,  Odutola A, Ndiaye M, Sahito SM, Osuorah CD,  Manjang A, Jarju S [...]   Ceesay L, Lowe-Jallow Y,  Sambou S, Jasseh M, Antonio M, Greenwood B, Kampmann B, Mulholland K,  Corrah T,  Howie SRC, Increased Disease due to Haemophilus influenzae Type b: Population-Based Surveillance in Eastern Gambia, 2008–2013 PIDJ 2015; 34(5):e107-12.
  6. Idoko OT, Roberts E, Cox M, Jafali J, Njie-Jobe J, Mackenzie, G, Ota MO, Kampmann B. Antibodies against Haemophilus influenzae type B in The Gambia: Investigating the extent of protection across age groups Vaccine 2014: 6; 4620-4.
  7. Idoko OT, Owolabi OA, Owiafe PK, Moris P, Odutola A, Bollaerts A, Ogundare E, Jongert E,  Demoitie M, Ofori-Aniyam O, Ota MO. Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine when given as a booster to BCG in Gambian infants: An open-label randomized controlled trial Tuberculosis 2014: 94; 564 - 578.
  8. Idoko OT, Okolo SN, Plikaytis B, Akinsola AA, Viviani S, Kulkarni P, Borrow R, Carlone G, Findlow H, Ellie C, Preziosi MP, Ota MOC, Kampmann B. The impact of pre-existing antibody on subsequent immune responses to meningococcal A containing vaccines. Vaccine 2014: 32; 4220-7.
  9. Idoko O, Kochhar S, Agbenyega T, Ogutu B, Ota M, Impact, Challenges and Future Projections of Vaccine Trials in Africa. AJTMH 2013: 88; 414–419.
  10. Samba O. Sow, M.D., Brown J. Okoko, M.D., M.P.H., Aldiouma Diallo, M.D., M.P.H., Simonetta Viviani, M.D., Ray Borrow, Ph.D., George Carlone, Ph.D., Milagritos Tapia, M.D., Adebayo K. Akinsola, M.D., Pascal Arduin, M.Sc., Helen Findlow, Ph.D., Cheryl Elie, M.Sc., Fadima Cheick Haidara, M.D., Richard A. Adegbola, Ph.D., F.R.C.Path., Doudou Diop, M.D., Varsha Parulekar, M.Sc., Julie Chaumont, M.Sc., Lionel Martellet, M.A., Fatoumata Diallo, M.D., Olubukola T. Idoko, M.D., Yuxiao Tang, Ph.D., Brian D. Plikaytis, M.Sc., Prasad S. Kulkarni, M.D., Elisa Marchetti, Ph.D., F. Marc LaForce, M.D., and Marie-Pierre Preziosi, M.D., Ph.D. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med 2011; 364: 2293-304.


       Research Interests

  • Paediatric vaccines
  • New-born/infant development
  • Precisions vaccines/medicine/interventions in context



  • Exploring the relationship between nutrition and vaccine responses
  • Seroepidemiology study of Zika virus and other arboviral fevers in selected West African countries
  • Characterizing global molecular (“OMIC”) signatures induced by EPI vaccines in infancy. Dec 2015 to Date
  • Maternal Immunisation with MenAfriVac® June 2015 – Date
  • Impact of inactivated poliovirus vaccine (IPV) introduction on healthcare providers’ and infant caregivers’ attitudes and practices in The Gambia. Jan –Nov 2015
  • A Phase 3 randomized, open-label trial to evaluate the safety, tolerability and immunogenicity of 13-valent pneumococcal conjugate vaccine formulated in multidose vials given with routine paediatric vaccinations in healthy infants. 2013 -2015
  • Antibody persistence to polio and Hib antigens in Gambians. 2011-2012
  • Meningitis Vaccine Project Seroprevalence study of antibody persistence 4 – 5 years after vaccination with MenAfriVac. 2011 -2012